Shareholders' Equity (Tables)
|
12 Months Ended |
Dec. 31, 2022 |
|---|
| Shareholders' Equity [Abstract] |
|
| Schedule of composed of common stock and Non-voting common stock |
| |
|
December 31 2022 |
|
| |
|
Authorized |
|
|
Issued and outstanding |
|
| |
|
Number of shares |
|
| Common stock |
|
|
30,000,000 |
|
|
|
17,379,861 |
|
| Non-voting Common stock |
|
|
2,803,774 |
|
|
|
- |
|
| |
|
|
|
| |
|
December 31 2021 |
|
| |
|
Authorized |
|
|
Issued and outstanding |
|
| |
|
Number of shares |
|
| Common stock |
|
|
11,009,315 |
|
|
|
2,050,404 |
|
| Non-voting Common stock |
|
|
2,803,774 |
|
|
|
1,783,773 |
|
|
| Schedule of awards granted |
| Award Type (2015 Plan) |
|
Number of Awards |
|
|
Vesting Conditions |
|
Expiration Date |
| Options |
|
|
167,779 |
|
|
Over 4 years from grant date-25% every year |
|
10th anniversary of Grant Date |
| RSU |
|
|
592,000 |
|
|
Over 3 years from grant date |
|
|
|
| Schedule of share option activity under option plans |
| |
|
Number of Options |
|
|
Weighted- Average Exercise Price |
|
|
Weighted Average Remaining Contractual Life |
|
| Outstanding – January 1, 2022 |
|
|
890,493 |
|
|
$ |
0.1518 |
|
|
|
5.43 |
|
| Granted |
|
|
167,779 |
|
|
$ |
2.1964 |
|
|
|
|
|
| Exercised |
|
|
(77,749 |
) |
|
$ |
0.0812 |
|
|
|
|
|
| Expired and forfeited |
|
|
(15,937 |
) |
|
$ |
1.5089 |
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Outstanding – December 31, 2022 |
|
|
964,586 |
|
|
$ |
0.4891 |
|
|
|
5.34 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Exercisable – December 31, 2022 |
|
|
771,956 |
|
|
$ |
0.1476 |
|
|
|
4.36 |
|
| |
|
Number of Options |
|
|
Weighted- Average Exercise Price |
|
|
Weighted Average Remaining Contractual Life |
|
| Outstanding – January 1, 2021 |
|
|
879,251 |
|
|
$ |
0.0874 |
|
|
|
6.25 |
|
| Granted |
|
|
43,261 |
|
|
$ |
1.3616 |
|
|
|
|
|
| Exercised |
|
|
(2,763 |
) |
|
$ |
0.1058 |
|
|
|
|
|
| Expired and forfeited |
|
|
(29,256 |
) |
|
$ |
0.0874 |
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Outstanding – December 31, 2021 |
|
|
890,493 |
|
|
$ |
0.1518 |
|
|
|
5.43 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Exercisable – December 31, 2021 |
|
|
801,562 |
|
|
$ |
0.276 |
|
|
|
5.10 |
|
|
| Schedule of ordinary shares issuable upon outstanding options and exercisable options |
| Exercise price |
|
Options
outstanding as of
December 31,
2022 |
|
|
Weighted
average
remaining
contractual
life (years) |
|
|
Options
exercisable as of
December 31,
2022 |
|
|
Weighted
average
remaining
contractual
life (years) |
|
| 0.0644 |
|
|
312,357 |
|
|
|
2.61 |
|
|
|
312,357 |
|
|
|
2.61 |
|
| 0.1058 |
|
|
449,885 |
|
|
|
5.43 |
|
|
|
437,516 |
|
|
|
5.39 |
|
| 0.5780 |
|
|
88,431 |
|
|
|
9.96 |
|
|
|
- |
|
|
|
- |
|
| 1.3616 |
|
|
38,912 |
|
|
|
8.41 |
|
|
|
15,472 |
|
|
|
8.41 |
|
| 4 |
|
|
75,001 |
|
|
|
9.2 |
|
|
|
6,611 |
|
|
|
9.7 |
|
|
| Schedule of fair value of the share options granted |
| |
|
Year Ended December 31 |
|
| |
|
2022 |
|
|
2021 |
|
| Expected term of options (years) |
|
|
10 |
|
|
|
5.4 |
|
| Expected common stock price volatility* |
|
|
54 |
% |
|
|
58 |
% |
| Expected dividend rate |
|
|
0 |
% |
|
|
0 |
% |
| Risk-free interest rate |
|
|
3.21%-3.25 |
% |
|
|
0.97 |
% |
|
| Schedule of share-based compensation expense for share options |
| |
|
Year Ended December 31 |
|
| |
|
2022 |
|
|
2021 |
|
| Cost of revenues |
|
|
3 |
|
|
|
3 |
|
| Research and development |
|
|
26 |
|
|
|
24 |
|
| Sales and marketing |
|
|
11 |
|
|
|
16 |
|
| General and administrative |
|
|
12 |
|
|
|
10 |
|
| Total Share-based compensation expense |
|
|
52 |
|
|
|
53 |
|
|
| Schedule of RSUs outstanding |
| |
|
December 31 2022 |
|
| |
|
Number of RSUs |
|
|
Weighted-
Average Grant
Date Fair Value |
|
| RSUs outstanding at the beginning of the year |
|
|
- |
|
|
|
- |
|
| Granted during the year |
|
|
592,000 |
|
|
$ |
1.62 |
|
| Exercised during the year |
|
|
- |
|
|
|
- |
|
| Forfeited during the year |
|
|
- |
|
|
|
- |
|
| Outstanding at the end of the year |
|
|
592,000 |
|
|
$ |
1.62 |
|
|
| Schedule of share-based compensation expense for RSUs |
| |
|
Year Ended December 31 |
|
| |
|
2022 |
|
|
2021 |
|
| |
|
U.S. dollars in thousands |
|
| Research and development |
|
|
21 |
|
|
|
- |
|
| Sales and marketing |
|
|
12 |
|
|
|
- |
|
| General and administrative |
|
|
135 |
|
|
|
- |
|
| Total Share-based compensation expense |
|
|
168 |
|
|
|
- |
|
|